Therapeutic Classification: antipsychotics, mood stabilizers
Pharmacologic Classification: serotonin-dopamine activity modulators (SDAM)
BEERS REMS
Absorption: Well absorbed (87%) following oral administration; 100% following IM injection.
Distribution: Extensive extravascular distribution.
Protein Binding: >99%.
Half-Life: Aripiprazole: 75 hr; dehydro-aripiprazole: 94 hr; ER injectable suspension: 3046 days (Abilify Maintena); 2935 days (Aristada)
Contraindicated in:
Use Cautiously in:
CV: bradycardia, chest pain, edema, hypertension, orthostatic hypotension, tachycardia
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), dry skin, ecchymosis, skin ulcer, sweating
EENT: blurred vision, conjunctivitis, ear pain
Endo: ↓prolactin, hyperglycemia
GI: constipation, ↑salivation, anorexia, nausea, vomiting
Hemat: AGRANULOCYTOSIS, anemia, leukopenia, neutropenia
MS: muscle cramps, neck pain
Neuro: drowsiness, extrapyramidal reactions, tremor, abnormal gait, akathisia, confusion, depression, fatigue, hostility, impaired cognitive function, impulse control disorders (eating/binge eating, gambling, sexual, shopping), insomnia, lightheadedness, manic reactions, nervousness, restlessness, sedation, SEIZURES, SUICIDAL THOUGHTS, tardive dyskinesia
Resp: dyspnea
Misc: ↓heat regulation, HYPERSENSITIVITY REACTIONS, injection site reactions, NEUROLEPTIC MALIGNANT SYNDROME
Drug-drug:
Schizophrenia
Acute Manic or Mixed Episodes Associated with Bipolar I Disorder
Maintenance Treatment of Bipolar I Disorder
Depression
Irritability Associated with Autistic Disorder
Tourette's Disorder
Lab Test Considerations:
NDC Code